vs

Side-by-side financial comparison of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) and Waters Corporation (WAT). Click either name above to swap in a different company.

Waters Corporation is the larger business by last-quarter revenue ($932.4M vs $44.6M, roughly 20.9× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). Waters Corporation runs the higher net margin — 24.2% vs -90.4%, a 114.6% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs 6.8%). Over the past eight quarters, Waters Corporation's revenue compounded faster (21.0% CAGR vs 7.3%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Waters Corporation is an American company headquartered in Milford, Massachusetts that provides analytical instruments and software used for chromatography, mass spectrometry, laboratory informatics, and rheometry by the life sciences, materials, and food industries.

PACB vs WAT — Head-to-Head

Bigger by revenue
WAT
WAT
20.9× larger
WAT
$932.4M
$44.6M
PACB
Growing faster (revenue YoY)
PACB
PACB
+7.0% gap
PACB
13.8%
6.8%
WAT
Higher net margin
WAT
WAT
114.6% more per $
WAT
24.2%
-90.4%
PACB
Faster 2-yr revenue CAGR
WAT
WAT
Annualised
WAT
21.0%
7.3%
PACB

Income Statement — Q4 2025 vs Q4 2025

Metric
PACB
PACB
WAT
WAT
Revenue
$44.6M
$932.4M
Net Profit
$-40.4M
$225.2M
Gross Margin
37.1%
61.1%
Operating Margin
-92.3%
29.0%
Net Margin
-90.4%
24.2%
Revenue YoY
13.8%
6.8%
Net Profit YoY
-1802.7%
-2.7%
EPS (diluted)
$-0.11
$3.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PACB
PACB
WAT
WAT
Q4 25
$44.6M
$932.4M
Q3 25
$38.4M
$799.9M
Q2 25
$39.8M
$771.3M
Q1 25
$37.2M
$661.7M
Q4 24
$39.2M
$872.7M
Q3 24
$40.0M
$740.3M
Q2 24
$36.0M
$708.5M
Q1 24
$38.8M
$636.8M
Net Profit
PACB
PACB
WAT
WAT
Q4 25
$-40.4M
$225.2M
Q3 25
$-38.0M
$148.9M
Q2 25
$-41.9M
$147.1M
Q1 25
$-426.1M
$121.4M
Q4 24
$2.4M
$231.4M
Q3 24
$-60.7M
$161.5M
Q2 24
$-173.3M
$142.7M
Q1 24
$-78.2M
$102.2M
Gross Margin
PACB
PACB
WAT
WAT
Q4 25
37.1%
61.1%
Q3 25
41.4%
59.0%
Q2 25
36.9%
58.3%
Q1 25
-3.7%
58.2%
Q4 24
25.6%
60.1%
Q3 24
25.0%
59.3%
Q2 24
16.5%
59.3%
Q1 24
29.1%
58.9%
Operating Margin
PACB
PACB
WAT
WAT
Q4 25
-92.3%
29.0%
Q3 25
-101.1%
24.0%
Q2 25
-112.8%
24.4%
Q1 25
-1154.5%
22.9%
Q4 24
-390.1%
33.5%
Q3 24
-160.3%
28.5%
Q2 24
-488.3%
26.7%
Q1 24
-209.6%
21.0%
Net Margin
PACB
PACB
WAT
WAT
Q4 25
-90.4%
24.2%
Q3 25
-98.9%
18.6%
Q2 25
-105.4%
19.1%
Q1 25
-1146.8%
18.3%
Q4 24
6.0%
26.5%
Q3 24
-151.9%
21.8%
Q2 24
-481.3%
20.1%
Q1 24
-201.4%
16.0%
EPS (diluted)
PACB
PACB
WAT
WAT
Q4 25
$-0.11
$3.76
Q3 25
$-0.13
$2.50
Q2 25
$-0.14
$2.47
Q1 25
$-1.44
$2.03
Q4 24
$-0.44
$3.88
Q3 24
$-0.22
$2.71
Q2 24
$-0.64
$2.40
Q1 24
$-0.29
$1.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PACB
PACB
WAT
WAT
Cash + ST InvestmentsLiquidity on hand
$279.5M
$587.8M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$5.3M
$2.6B
Total Assets
$784.1M
$5.1B
Debt / EquityLower = less leverage
0.55×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PACB
PACB
WAT
WAT
Q4 25
$279.5M
$587.8M
Q3 25
$298.7M
$459.1M
Q2 25
$314.7M
$367.2M
Q1 25
$343.1M
$382.9M
Q4 24
$389.9M
$325.4M
Q3 24
$471.1M
$331.5M
Q2 24
$509.8M
$327.4M
Q1 24
$561.9M
$338.2M
Total Debt
PACB
PACB
WAT
WAT
Q4 25
$1.4B
Q3 25
Q2 25
Q1 25
Q4 24
$1.6B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
PACB
PACB
WAT
WAT
Q4 25
$5.3M
$2.6B
Q3 25
$36.1M
$2.3B
Q2 25
$61.5M
$2.2B
Q1 25
$91.6M
$2.0B
Q4 24
$506.6M
$1.8B
Q3 24
$453.1M
$1.6B
Q2 24
$492.7M
$1.4B
Q1 24
$649.0M
$1.3B
Total Assets
PACB
PACB
WAT
WAT
Q4 25
$784.1M
$5.1B
Q3 25
$803.2M
$4.9B
Q2 25
$825.5M
$4.7B
Q1 25
$860.8M
$4.6B
Q4 24
$1.3B
$4.6B
Q3 24
$1.5B
$4.5B
Q2 24
$1.5B
$4.4B
Q1 24
$1.7B
$4.5B
Debt / Equity
PACB
PACB
WAT
WAT
Q4 25
0.55×
Q3 25
Q2 25
Q1 25
Q4 24
0.89×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PACB
PACB
WAT
WAT
Operating Cash FlowLast quarter
$-19.1M
$164.6M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-44.6%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
0.73×
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PACB
PACB
WAT
WAT
Q4 25
$-19.1M
$164.6M
Q3 25
$-18.7M
$187.3M
Q2 25
$-29.4M
$41.1M
Q1 25
$-44.1M
$259.6M
Q4 24
$-30.6M
$240.1M
Q3 24
$-45.5M
$204.6M
Q2 24
$-54.3M
$54.5M
Q1 24
$-75.7M
$262.9M
Free Cash Flow
PACB
PACB
WAT
WAT
Q4 25
$-19.9M
Q3 25
$-18.8M
Q2 25
$-29.9M
Q1 25
$-45.4M
Q4 24
$-32.3M
Q3 24
$-46.3M
Q2 24
$-55.7M
Q1 24
$-79.6M
FCF Margin
PACB
PACB
WAT
WAT
Q4 25
-44.6%
Q3 25
-48.9%
Q2 25
-75.3%
Q1 25
-122.3%
Q4 24
-82.3%
Q3 24
-115.7%
Q2 24
-154.8%
Q1 24
-205.0%
Capex Intensity
PACB
PACB
WAT
WAT
Q4 25
1.9%
Q3 25
0.2%
Q2 25
1.4%
Q1 25
3.7%
Q4 24
4.1%
Q3 24
2.0%
Q2 24
4.1%
Q1 24
10.0%
Cash Conversion
PACB
PACB
WAT
WAT
Q4 25
0.73×
Q3 25
1.26×
Q2 25
0.28×
Q1 25
2.14×
Q4 24
-12.93×
1.04×
Q3 24
1.27×
Q2 24
0.38×
Q1 24
2.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

WAT
WAT

Segment breakdown not available.

Related Comparisons